Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

Katarina Le Blanc(Karolinska Institutet), Ida Rasmusson(Karolinska Institutet), Berit Sundberg(Karolinska Institutet), Cecilia Götherström(Karolinska Institutet), Moustapha Hassan(Karolinska University Hospital), Mehmet Uzunel(Karolinska Institutet), Olle Ringdén(Karolinska Institutet)
The Lancet
May 1, 2004
10.1016/s0140-6736(04)16104-7
Cited by 2,731

Abstract

Related Papers

Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex
Katarina Le Blanc, L Tammik, Berit Sundberg et al.|Scandinavian Journal of Immunology|2003|1.4k
Rapid Hematopoietic Recovery After Coinfusion of Autologous-Blood Stem Cells and Culture-Expanded Marrow Mesenchymal Stem Cells in Advanced Breast Cancer Patients Receiving High-Dose Chemotherapy
Omer N. Koç, Stanton L. Gerson, Brenda Cooper et al.|Journal of Clinical Oncology|2000|1.1k
Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates
Steven M. Devine, Carrington Cobbs, Matt Jennings et al.|Blood|2003|751
The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia
Mehmet Uzunel, Jonas Mattsson, Marie Jaksch et al.|Blood|2001|100